-
公开(公告)号：EP2662386B1
公开(公告)日：2019-03-06
申请号：EP12003552.2
申请日：2012-05-07
申请人： Astellas Pharma Inc. , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH , Universitätsmedizin der Johannes Gutenberg-Universität Mainz
-
2.发明公开Antibodies that bind to PLAC1 and block interaction between PLAC1 and FGF7 审中-公开Antikörper，die an PLAC1 binden und die Wechselwirkung zwischen PLAC1 und FGF7 inhibitioni
公开(公告)号：EP2662386A1
公开(公告)日：2013-11-13
申请号：EP12003552.2
申请日：2012-05-07
申请人： BioNTech AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH , Universitätsmedizin der Johannes Gutenberg-Universität Mainz
发明人： Sahin, Ugur , Koslowski, Michael , Grimmler, Matthias , Barea Roldàn, Diana , Hartmann, Christoph , Hubich, Stefanie
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/76
摘要： According to the invention, it has been observed that PLAC interacts with FGF7 and that PLAC1, FGF7 and FGFR2IIIb can form a trimeric complex. Furthermore, it has been observed that PLAC1 acts as co-factor for FGF7-mediated specific phosphorylation of FGFR2IIIb thus enhancing proliferation and migration of cells. The present invention provides antibodies and antibody mixtures blocking the interaction between PLAC1 and FGF7. These antibodies and antibody mixtures are useful in the treatment of cancer.
摘要翻译： 根据本发明，已经观察到PLAC与FGF7相互作用，PLAC1，FGF7和FGFR2IIIb可以形成三聚体复合物。 此外，已经观察到PLAC1作为FGF7介导的FGFR2IIIb的特异性磷酸化的辅因子，从而增强细胞的增殖和迁移。 本发明提供了阻断PLAC1和FGF7之间相互作用的抗体和抗体混合物。 这些抗体和抗体混合物可用于治疗癌症。
-
3.发明公开Tumor vaccination involving a humoral immune response against self-proteins 审中-公开Tumorvakzinierung，死亡humorale Immunantwort gegen Selbstproteine beinhaltet
公开(公告)号：EP2366709A1
公开(公告)日：2011-09-21
申请号：EP10002775.4
申请日：2010-03-16
发明人： Klamp, Thorsten , Sahin, Ugur , Türeci,Özlem , Koslowski, Michael , Hiller, Thomas , Schumacher, Jens
CPC分类号： C07K14/4748 , A61K39/0011 , A61K2039/5256 , A61K2039/6075 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2730/10122 , C12N2730/10123
摘要： The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
摘要翻译： 本发明涉及使用包含全部或部分乙型肝炎病毒核心抗原蛋白的嵌合蛋白和包含衍生自肿瘤相关抗原的细胞外部分的表位的氨基酸序列的肿瘤免疫治疗，特别是肿瘤免疫治疗。 特别地，本发明提供了包含所述嵌合蛋白的病毒样颗粒，其可用于在受试者中针对肿瘤相关抗原，特别是针对在其表面上携带所述肿瘤相关抗原的细胞引起体液免疫应答，其中 肿瘤相关抗原是所述受试者的自身蛋白质。
-
-
搜索结果
3 条记录 (耗时 0.023 秒)
